Compare NVAX & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NVAX | EVO |
|---|---|---|
| Founded | 1987 | 1993 |
| Country | United States | Germany |
| Employees | N/A | 4553 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 934.1M |
| IPO Year | 1996 | N/A |
| Metric | NVAX | EVO |
|---|---|---|
| Price | $9.14 | $2.69 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 1 |
| Target Price | ★ $11.33 | $7.00 |
| AVG Volume (30 Days) | ★ 4.7M | 94.1K |
| Earning Date | 05-06-2026 | 04-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 309.76 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,123,479,000.00 | N/A |
| Revenue This Year | N/A | $1.37 |
| Revenue Next Year | N/A | $10.05 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 64.69 | N/A |
| 52 Week Low | $6.20 | $2.31 |
| 52 Week High | $11.85 | $4.80 |
| Indicator | NVAX | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 53.16 | 36.25 |
| Support Level | $7.75 | $2.32 |
| Resistance Level | $10.66 | $3.78 |
| Average True Range (ATR) | 0.64 | 0.09 |
| MACD | 0.11 | -0.06 |
| Stochastic Oscillator | 45.56 | 6.44 |
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.